Guided Therapeutics, Inc.
GTHP
$0.25
$0.0525.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 450.85% | 76,600.00% | 10,857.14% | 368.42% | 210.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 450.85% | 76,600.00% | 10,857.14% | 368.42% | 210.53% |
| Cost of Revenue | 282.93% | 6,400.00% | 3,800.00% | 266.67% | 86.36% |
| Gross Profit | 540.26% | 28,700.00% | 28,500.00% | 460.00% | 381.25% |
| SG&A Expenses | 38.31% | 78.23% | 73.26% | 110.30% | 95.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.15% | 52.30% | 61.12% | 74.71% | 68.22% |
| Operating Income | 1.17% | -16.93% | -25.29% | -66.26% | -64.30% |
| Income Before Tax | -20.48% | -33.95% | -32.31% | -22.36% | -17.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.48% | -33.95% | -32.31% | -22.36% | -17.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.48% | -33.95% | -32.31% | -22.36% | -17.02% |
| EBIT | 1.17% | -16.93% | -25.29% | -66.26% | -64.30% |
| EBITDA | 1.18% | -16.96% | -25.35% | -66.72% | -64.73% |
| EPS Basic | -1.94% | -6.39% | 6.87% | 9.15% | 7.21% |
| Normalized Basic EPS | 11.89% | 7.31% | 9.63% | -26.29% | -31.18% |
| EPS Diluted | 11.85% | 14.39% | 16.94% | -12.81% | -12.96% |
| Normalized Diluted EPS | 11.89% | 7.31% | 9.63% | -26.29% | -31.18% |
| Average Basic Shares Outstanding | 32.33% | 37.50% | 36.66% | 31.67% | 23.62% |
| Average Diluted Shares Outstanding | 32.33% | 37.50% | 36.66% | 31.67% | 23.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |